Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
NCT04669171 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination with lenalidomide and/or rituximab in patients with indolent NHL
Conditions Studied
Interventions
- BIOLOGICAL rituximab
- DRUG lenalidomide
- BIOLOGICAL EO2463
Study Locations (12)
Other
- CHU d'Amiens-Picardie - Hopital SUD — Amiens
- University of Bologna — Bologna
- IRCCS Policlinico San Matteo Foundation - University of Pavia — Naples
- IRCCS Policlinico San Matteo Foundation - University of Pavia — Pavia
- University Hospital Vall d'Hebron, Institute of Oncology — Barcelona
- Clinica Universidad de Navarra — Madrid
- Clinica Universidad de Navarra — Pamplona
- Hospital Clinico Universitario de Salamanca — Salamanca
Massachusetts
- Dana Farber Cancer Institute — Boston
Minnesota
- Mayo Clinic — Rochester
New York
- University of Rochester Medical Center (URMC) - Wilmot Cancer Institute (WCI) (James P. Wilmot Cancer Center) — Rochester
Washington
- University of Washington-Seattle Cancer Care Alliance — Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2021-07-05 |
| Est. Completion | 2034-05-30 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04669171
The ClinicalTrials.gov registry entry for NCT04669171 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Enterome, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Follicular Lymphoma appearing as the primary indexed condition, and to 3 interventions — of which rituximab is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04669171 reports 12 study locations spanning 5 distinct geographic areas — top geographies include Other, Massachusetts, Minnesota. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04669171 about?
NCT04669171 is a clinical study titled "A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma". The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination with lenalidomide and/or rituximab in patients with indolent NHL
What is the current status of trial NCT04669171?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2021-07-05. Estimated completion is 2034-05-30.
What conditions does trial NCT04669171 study?
This clinical trial studies the following conditions: Follicular Lymphoma, Marginal Zone Lymphoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04669171?
The interventions under investigation include: rituximab (BIOLOGICAL), lenalidomide (DRUG), EO2463 (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04669171?
This trial is sponsored by Enterome, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04669171 being conducted?
This trial has 12 study locations across Massachusetts, Minnesota, New York, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.